Physician profile
Alan Einstein
NPI 1740306943
$4,321.45
in general payments reported to CMS, 2019-2025
36 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $673 · 2021: $1,693 · 2022: $892 · 2023: $498 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.67 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.07 | 2020-2023 | |
| Novo Nordisk INC | $485.30 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Allergan, INC. | $304.57 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $234.34 | 2021-2022 | |
| Abbott Laboratories | $222.93 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $202.23 | 2021-2023 | Xarelto |
| Lilly USA, LLC | $200.58 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Ibsa Pharma INC. | $198.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $186.43 | 2019-2023 | Breztri |
| Corium, LLC | $180.98 | 2022-2023 | Azstarys |
| Eisai INC. | $172.68 | 2021 | |
| Amgen INC. | $158.63 | 2020-2023 | Repatha |
| Jazz Pharmaceuticals INC. | $135.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.60 | 2019-2021 | |
| Daiichi Sankyo INC. | $120.61 | 2020-2023 | Injectafer |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Einstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.